# EDGAR Filing Document

**Accession Number:** 0001708331
**File Stem:** 0001213900-23-023675
**Filing Date:** 2023-3
**Character Count:** 13488
**Document Hash:** 54f32e0a237e764edc1e674d20fa91a9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-023675.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001213900-23-023675

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230324

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230328

**DATE AS OF CHANGE**: 20230328

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Virpax Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001708331
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 821510982
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40064
- **FILM NUMBER:** 23769508

**BUSINESS ADDRESS:**
- **STREET 1:** 1055 WESTLAKES DRIVE, SUITE 300
- **CITY:** BERWYN
- **STATE:** PA
- **ZIP:** 19312
- **BUSINESS PHONE:** 610-727-4597

**MAIL ADDRESS:**
- **STREET 1:** 1055 WESTLAKES DRIVE, SUITE 300
- **CITY:** BERWYN
- **STATE:** PA
- **ZIP:** 19312

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virpax Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20170602

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

 **Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 24, 2023**

**Virpax Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40064** | **82-1510982** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission File Number) | (I.R.S. Employer<br> Identification No.) |

---

**1055 Westlakes Drive, Suite 300**

**Berwyn, PA 19312**

(Address of principal executive offices) (Zip Code)

**(610) 727-4597** 

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class:** | **Trading Symbol** | **Name of Each Exchange on which Registered** |
| Common Stock, par value $0.00001 per share | VRPX | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

***Appointment of Director***

 

On March 24, 2023, the Board of Directors (the "Board") of Virpax Pharmaceuticals, Inc. (the "Company") increased the size of the Board from eight to nine directors and appointed Ms. Barbara Ruskin to serve as a Class III director until the Company's 2025 annual meeting of stockholders, to fill the newly created vacancy. Ms. Ruskin has not been named to any committee of the Board at this time.

In connection with her appointment, Ms. Ruskin was granted an option to purchase 25,000 shares of the Company's common stock with an exercise price of $0.8364 per share, with all shares vesting on the twelve month anniversary of the date of grant, subject to Ms. Ruskin's continued service to the Company. The option grant is subject to the terms and conditions of the Company's Virpax Pharmaceuticals, Inc. 2022 Equity Incentive Plan and the related stock option agreement. Ms. Ruskin will also be compensated pursuant to the Company's standard practice for annual stock option grants to non-employee directors, as described in the Company's filings made with the Securities and Exchange Commission.

There are no family relationships between Ms. Ruskin and any other executive officers or directors of the Company. There is no arrangement or understanding between Ms. Ruskin and any other persons pursuant to which Ms. Ruskin was selected as director. In addition, Ms. Ruskin is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Company will enter into an indemnification agreement with Ms. Ruskin on the Company's standard form of indemnification agreement, a copy of which was previously filed with the U.S. Securities and Exchange Commission.

On March 28, 2023, the Company issued a press release announcing Ms. Ruskin's appointment to the Board. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit** |
| 99.1 | [Press release, dated March 28, 2023, issued by Virpax Pharmaceuticals, Inc.](ea175742ex99-1_virpax.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **VIRPAX PHARMACEUTICALS, INC.** | **VIRPAX PHARMACEUTICALS, INC.** |
| Dated: March 28, 2023 | By: | */s/ Anthony Mack* |
|  |  | Anthony Mack |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**![](image_001.jpg)

**Virpax Pharmaceuticals Announces Appointment of** 

**Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors**

**** 

**BERWYN, PA, March 28, 2023 — Virpax<sup>®</sup> Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX),** a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that the Company has appointed Barbara A. Ruskin, Ph.D, J.D. to its Board of Directors, increasing the size of the Board to nine members.

Dr. Ruskin, who received her Ph.D. in Biochemistry & Molecular Biology from Harvard University, is an experienced attorney specializing in life sciences and intellectual property. Most recently she serves as the Chief Intellectual Property and Innovation Officer for Silence Therapeutics, a Nasdaq listed international biotechnology company. Prior to that role, she was the Company's General Counsel and Chief Patent Officer. Dr. Ruskin brings over 25 years of experience in life science IP and corporate law, having served as outside counsel for pharmaceutical and biotechnology companies and their investors, including as an IP Corporate Partner at Ropes & Gray LLP and as an associate at Fish & Neave LLP, both in New York City. She has advised, managed and prosecuted worldwide patent portfolios for a number of biotech and pharmaceutical industry clients including Biogen, Stryker Biotech and Vertex Pharmaceuticals among others, and has also worked in IP litigation in both the U.S. and Europe. Dr. Ruskin previously served as Chairman and currently serves as a director on the Board of St. Jude Children's Hospital GMP, LLC and has previously served as a director on the Board of the Burke Neurological Institute.

Dr. Ruskin did her post-doctoral research at the Whitehead Institute for Biomedical Research (MIT) and at the Institute for Neuroscience (University of Oregon). She has published numerous scientific articles and given legal presentations that combine her knowledge of biochemistry and law. In addition to her Ph.D. in Biochemistry & Molecular Biology, Dr. Ruskin received a B.A. in Biochemistry from the University of California, Berkeley, and her J.D. from Fordham University School of Law.

"With her unique background, knowledge and experience, we believe that Dr. Ruskin will be a valuable addition to our Board. We are very pleased that she is joining us and look forward to her contributions," concluded Anthony P. Mack, Chairman and CEO of Virpax.

**About Virpax Pharmaceuticals**

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop two other product candidates. PES200 is a product candidate being developed to manage post-traumatic stress disorder (PTSD) and NobrXiol™ is a product candidate being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax recently acquired global rights to NobrXiol. Virpax is also seeking approval of two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube.

**Forward-Looking Statement**

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or the Company's financial performance and involve known and unknown risks, uncertainties, and other factors, including the Company's ability to successfully complete research and further development and commercialization of Company drug candidates in current or future indications; the uncertainties inherent in clinical testing; the Company's ability to manage and successfully complete clinical trials and the research and development efforts for multiple product candidates at varying stages of development; the effects of the outbreak of COVID-19 on the Company's business and results of operations; the timing, cost and uncertainty of obtaining regulatory approvals for the Company's product candidates; the Company's ability to protect its intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's product candidates; the Company's ability to continue to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete clinical trials that the Company plans to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q that the Company files with the U.S. Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

**Contact:**

Betsy Brod<br> Affinity Growth Advisors<br> betsy.brod@affinitygrowth.com<br> 212-661-2231